IP Library Granted Patent US 7,601,815
Granted Patent B2
US 7,601,815 · App. 11/434,646 · Granted Oct 13, 2009

Anti-CCL27 antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,601,815
App. No.
11/434,646
Granted
Oct 13, 2009
Kind
B2
Abstract

Novel CC chemokines from human, reagents related thereto including purified proteins, specific antibodies and nucleic acids encoding these chemokines are provided. Also provided are methods of making and using said reagents and diagnostic kits.

Claims (22)

1. An isolated antibody or antigen-binding fragment thereof that specifically binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 6 or to an antigenic fragment comprising 10 or more contiguous amino acids thereof.

2. The antibody or antigen-binding fragment of claim 1 wherein the polypeptide consists of 20 contiguous amino acids of SEQ ID NO: 6.

3. The antibody or antigen-binding fragment of claim 2 wherein the polypeptide consists of 30 contiguous amino acids of SEQ ID NO: 6.

4. The antibody or antigen-binding fragment of claim 3 wherein the polypeptide consists of 50 contiguous amino acids of SEQ ID NO: 6.

5. The antibody or antigen-binding fragment of claim 4 wherein the polypeptide consists of 70 contiguous amino acids of SEQ ID NO: 6.

6. An isolated antibody or antigen-binding fragment thereof that specifically binds a polypeptide consisting of the amino acid sequence of SEQ ID NO: 6.

7. An isolated monoclonal antibody that specifically binds a polypeptide consisting of the amino acid sequence of SEQ ID NO: 6.

8. The antibody or antigen-binding fragment of claim 1 which is a polyclonal antibody; a monoclonal antibody; a single chain antibody; a Fab fragment; an Fv fragment; a labeled antibody; a humanized antibody or an anti-idiotypic antibody.

9. The antibody or antigen-binding fragment of claim 8 which is labeled with a member selected from the group consisting of a radiolabel, peroxidase, alkaline phosphatase, biotin, avidin and 125 I.

10. The antibody or antigen-binding fragment of claim 6 which is a polyclonal antibody; a monoclonal antibody; a single chain antibody; a Fab fragment; an Fv fragment; a labeled antibody; a humanized antibody or an anti-idiotypic antibody.

11. The antibody or antigen-binding fragment of claim 10 which is labeled with a member selected from the group consisting of a radiolabel, peroxidase, alkaline phosphatase, biotin, avidin and 125 I.

12. The antibody of claim 7 which is a labeled antibody.

13. The antibody of claim 12 which is labeled with a member selected from the group consisting of a radiolabel, peroxidase, alkaline phosphatase, biotin, avidin and 125 I .

14. The antibody or antigen-binding fragment of claim 1 bound to said polypeptide.

15. The antibody or antigen-binding fragment of claim 6 bound to said polypeptide.

16. The antibody of claim 7 bound to said polypeptide.

17. The antibody or antigen-binding fragment of claim 1 immobilized on a solid substrate.

18. The antibody or antigen-binding fragment of claim 6 immobilized on a solid substrate.

19. The antibody of claim 7 immobilized on a solid substrate.

20. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 1 and a pharmaceutically acceptable carrier.

21. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 6 and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising the antibody of claim 7 and a pharmaceutically acceptable carrier.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →